Last reviewed · How we verify
Part A - single rising dose 1
At a glance
| Generic name | Part A - single rising dose 1 |
|---|---|
| Also known as | Single dose 1, Single dose 2, Single dose 3, Single dose 4, Single dose 5 |
| Sponsor | Brilliant Inspiration Biotherapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1 (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- A PhaseⅠ Study of HW252001 in Healthy Subjects (PHASE1)
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome (PHASE1)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part A - single rising dose 1 CI brief — competitive landscape report
- Part A - single rising dose 1 updates RSS · CI watch RSS
- Brilliant Inspiration Biotherapeutics portfolio CI